WO2014191806A2 - Effervescent formulations that deliver particles which float in the stomach - Google Patents
Effervescent formulations that deliver particles which float in the stomach Download PDFInfo
- Publication number
- WO2014191806A2 WO2014191806A2 PCT/IB2014/000825 IB2014000825W WO2014191806A2 WO 2014191806 A2 WO2014191806 A2 WO 2014191806A2 IB 2014000825 W IB2014000825 W IB 2014000825W WO 2014191806 A2 WO2014191806 A2 WO 2014191806A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- api
- release
- composition
- delayed
- effervescent
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 23
- 239000002245 particle Substances 0.000 title description 25
- 210000002784 stomach Anatomy 0.000 title description 12
- 238000009472 formulation Methods 0.000 title description 6
- 239000008186 active pharmaceutical agent Substances 0.000 claims abstract description 15
- 230000002496 gastric effect Effects 0.000 claims abstract description 14
- 239000000843 powder Substances 0.000 claims abstract description 13
- 230000003111 delayed effect Effects 0.000 claims abstract description 12
- 239000012530 fluid Substances 0.000 claims abstract description 10
- 239000008187 granular material Substances 0.000 claims abstract description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 10
- 239000007938 effervescent tablet Substances 0.000 claims abstract description 9
- 230000014759 maintenance of location Effects 0.000 claims abstract description 6
- 239000003651 drinking water Substances 0.000 claims abstract description 5
- 235000020188 drinking water Nutrition 0.000 claims abstract description 5
- 150000007524 organic acids Chemical class 0.000 claims abstract description 5
- 238000003756 stirring Methods 0.000 claims abstract description 5
- 239000003826 tablet Substances 0.000 claims abstract description 5
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims description 17
- 229960003105 metformin Drugs 0.000 claims description 13
- -1 polyethylene Polymers 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 10
- 239000004698 Polyethylene Substances 0.000 claims description 6
- 229920000573 polyethylene Polymers 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 4
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 claims description 3
- 229960001381 glipizide Drugs 0.000 claims description 3
- 239000004615 ingredient Substances 0.000 claims description 2
- 238000000576 coating method Methods 0.000 description 42
- 239000011248 coating agent Substances 0.000 description 31
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 28
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 27
- 239000000463 material Substances 0.000 description 14
- 229920000642 polymer Polymers 0.000 description 11
- 239000000377 silicon dioxide Substances 0.000 description 11
- 239000002253 acid Substances 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 8
- 229930006000 Sucrose Natural products 0.000 description 8
- 239000007771 core particle Substances 0.000 description 8
- 239000005720 sucrose Substances 0.000 description 8
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 7
- 229920003176 water-insoluble polymer Polymers 0.000 description 6
- 239000001993 wax Substances 0.000 description 6
- 239000011324 bead Substances 0.000 description 5
- 238000004090 dissolution Methods 0.000 description 5
- 238000007922 dissolution test Methods 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 229920003134 Eudragit® polymer Polymers 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 239000002195 soluble material Substances 0.000 description 4
- 229910002012 Aerosil® Inorganic materials 0.000 description 3
- 239000001856 Ethyl cellulose Substances 0.000 description 3
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 239000004372 Polyvinyl alcohol Substances 0.000 description 3
- 235000015165 citric acid Nutrition 0.000 description 3
- 238000012377 drug delivery Methods 0.000 description 3
- 238000009505 enteric coating Methods 0.000 description 3
- 239000002702 enteric coating Substances 0.000 description 3
- 235000019325 ethyl cellulose Nutrition 0.000 description 3
- 229920001249 ethyl cellulose Polymers 0.000 description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 description 3
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 3
- PYMYPHUHKUWMLA-UHFFFAOYSA-N 2,3,4,5-tetrahydroxypentanal Chemical compound OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 239000004203 carnauba wax Substances 0.000 description 2
- 235000013869 carnauba wax Nutrition 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002301 cellulose acetate Polymers 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- RRPFCKLVOUENJB-UHFFFAOYSA-L disodium;2-aminoacetic acid;carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O.NCC(O)=O RRPFCKLVOUENJB-UHFFFAOYSA-L 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000004051 gastric juice Anatomy 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 229920001477 hydrophilic polymer Polymers 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 230000000873 masking effect Effects 0.000 description 2
- 229960004329 metformin hydrochloride Drugs 0.000 description 2
- OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 description 2
- 229920000058 polyacrylate Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000011736 potassium bicarbonate Substances 0.000 description 2
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 2
- 235000015497 potassium bicarbonate Nutrition 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 235000011181 potassium carbonates Nutrition 0.000 description 2
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 235000017550 sodium carbonate Nutrition 0.000 description 2
- 229910000031 sodium sesquicarbonate Inorganic materials 0.000 description 2
- 235000018341 sodium sesquicarbonate Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229960002622 triacetin Drugs 0.000 description 2
- WCTAGTRAWPDFQO-UHFFFAOYSA-K trisodium;hydrogen carbonate;carbonate Chemical compound [Na+].[Na+].[Na+].OC([O-])=O.[O-]C([O-])=O WCTAGTRAWPDFQO-UHFFFAOYSA-K 0.000 description 2
- GQPYTJVDPQTBQC-KLQYNRQASA-N (3r)-3-amino-1-[3-(trifluoromethyl)-6,8-dihydro-5h-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-1-one;phosphoric acid;hydrate Chemical compound O.OP(O)(O)=O.C([C@H](CC(=O)N1CC=2N(C(=NN=2)C(F)(F)F)CC1)N)C1=CC(F)=C(F)C=C1F GQPYTJVDPQTBQC-KLQYNRQASA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- WCOXQTXVACYMLM-UHFFFAOYSA-N 2,3-bis(12-hydroxyoctadecanoyloxy)propyl 12-hydroxyoctadecanoate Chemical compound CCCCCCC(O)CCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC(O)CCCCCC)COC(=O)CCCCCCCCCCC(O)CCCCCC WCOXQTXVACYMLM-UHFFFAOYSA-N 0.000 description 1
- YUTUUOJFXIMELV-UHFFFAOYSA-N 2-Hydroxy-2-(2-methoxy-2-oxoethyl)butanedioic acid Chemical compound COC(=O)CC(O)(C(O)=O)CC(O)=O YUTUUOJFXIMELV-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 229920000178 Acrylic resin Polymers 0.000 description 1
- 239000004925 Acrylic resin Substances 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- HCVBQXINVUFVCE-UHFFFAOYSA-N Citronensaeure-beta-methylester Natural products COC(=O)C(O)(CC(O)=O)CC(O)=O HCVBQXINVUFVCE-UHFFFAOYSA-N 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- GHUUBYQTCDQWRA-UHFFFAOYSA-N Pioglitazone hydrochloride Chemical compound Cl.N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 GHUUBYQTCDQWRA-UHFFFAOYSA-N 0.000 description 1
- 229920003072 Plasdone™ povidone Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 229940123518 Sodium/glucose cotransporter 2 inhibitor Drugs 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241001611608 Systena Species 0.000 description 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229920013820 alkyl cellulose Polymers 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 210000001815 ascending colon Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- QHIWVLPBUQWDMQ-UHFFFAOYSA-N butyl prop-2-enoate;methyl 2-methylprop-2-enoate;prop-2-enoic acid Chemical compound OC(=O)C=C.COC(=O)C(C)=C.CCCCOC(=O)C=C QHIWVLPBUQWDMQ-UHFFFAOYSA-N 0.000 description 1
- 238000001354 calcination Methods 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000008199 coating composition Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 229960005168 croscarmellose Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000012943 hotmelt Substances 0.000 description 1
- 239000000416 hydrocolloid Substances 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 229940090473 januvia Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000003750 lower gastrointestinal tract Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- IQSHMXAZFHORGY-UHFFFAOYSA-N methyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound COC(=O)C=C.CC(=C)C(O)=O IQSHMXAZFHORGY-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- WRMXOVHLRUVREB-UHFFFAOYSA-N phosphono phosphate;tributylazanium Chemical compound OP(O)(=O)OP([O-])([O-])=O.CCCC[NH+](CCCC)CCCC.CCCC[NH+](CCCC)CCCC WRMXOVHLRUVREB-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229960002827 pioglitazone hydrochloride Drugs 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 229940088417 precipitated calcium carbonate Drugs 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 229960002354 repaglinide Drugs 0.000 description 1
- 239000012508 resin bead Substances 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229960003271 rosiglitazone maleate Drugs 0.000 description 1
- SUFUKZSWUHZXAV-BTJKTKAUSA-N rosiglitazone maleate Chemical compound [H+].[H+].[O-]C(=O)\C=C/C([O-])=O.C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O SUFUKZSWUHZXAV-BTJKTKAUSA-N 0.000 description 1
- 229960004937 saxagliptin Drugs 0.000 description 1
- QGJUIPDUBHWZPV-SGTAVMJGSA-N saxagliptin Chemical compound C1C(C2)CC(C3)CC2(O)CC13[C@H](N)C(=O)N1[C@H](C#N)C[C@@H]2C[C@@H]21 QGJUIPDUBHWZPV-SGTAVMJGSA-N 0.000 description 1
- 108010033693 saxagliptin Proteins 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229960004115 sitagliptin phosphate Drugs 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000009494 specialized coating Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 235000011044 succinic acid Nutrition 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 229920003002 synthetic resin Polymers 0.000 description 1
- 239000000057 synthetic resin Substances 0.000 description 1
- RTZRUVMEWWPNRR-UHFFFAOYSA-N tert-butyl n-(3-iodo-1h-pyrrolo[2,3-b]pyridin-5-yl)carbamate Chemical compound CC(C)(C)OC(=O)NC1=CN=C2NC=C(I)C2=C1 RTZRUVMEWWPNRR-UHFFFAOYSA-N 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 239000001069 triethyl citrate Substances 0.000 description 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
- 235000013769 triethyl citrate Nutrition 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
Definitions
- Sustained- or delayed-release pharmaceutical compositions are well known and generally employ specialized coatings based on pH or water solubility effects, placed on the active phannaeeutieal ingredient (API), ft is also known that drug release rates can be delayed or controlled by delivering an API to the stomach m a floating drug delivery system having a bulk density less than gastric fluid, which system remains buoyant in the stomach for an extended period of time and increases the gastric retention time (GRT).
- GRT gastric retention time
- Floating drug delivery systems include gas-generating and non-effervescent systems. Delayed-release coatings that depend on pH or water solubility effects are sometimes combined with floating systems.
- Non-effervescent floating systems typically contain cellulose derivatives like starch and a higher fatty alcohol or fatly acid glyeerkle, bilayer compressed capsules, multilayered flexible sheet-like medicament devices, hollow microspheres of acrylic resins, polystyrene floatable shells, single and multiple unit devices with floatation chambers and microporous compartments and buoyant controlled release powder formulations, or hydrogels that expand to hundreds of times their dehydrated form when immersed in water. Oral drug delivery formulations made from these gels swell rapidly in the stomach, causing medications to move more slowly from the stomach to the intestines and be absorbed more efficiently by the body.
- Gas-generating systems typically use effervescent components such as sodium bicarbonate, citric acid and tartaric acid.
- effervescent components such as sodium bicarbonate, citric acid and tartaric acid.
- the stoichiometric ratio of citric acid and sodium bicarbonate optimal for gas generation is 0,76:1.
- the common approach for preparing these systems involves resin beads loaded with bicarbonate and coated with ethyl cellulose.
- the insoluble coating allows permeation of water causing carbon dioxide to release arid the beads to float in the stomach
- Other appfoacb.es include the use of highly swellable hydrocolloids arid light mineral oils,- a mixture of sodium alginate and sodium bicarbonate, multiple unit floating pills that generate carbon dioxide when ingested, floating minicapsules with a core of sodium bicarbonate, lacotes and polyvinyl pytrolodone coats with hydroxypropyl methykeliulose, and floating systems based on ion exchange resin technology- Prior to the present invention, one would not expect to combine an effervescent floating system with a conventional effervescent tablet formulation for dissolving in water before ingestion by the patient.
- An object of the present invention is to provide a delayed-release pharmaceutical composition, comprising: an effervescent tablet, granule, or powder containing a first effervescing organic acid component and a first effervescing base component, wherein said tablet, granule, or powder is completely solubilized. in drinking water at 25 °C within 2 minutes without stirring; and an effective amount of active pharmaceutical ingredient (API) coated with a delayed- release effervescent floating delivery system containing a second, effervescing base component, which system is buoyant in gastric fluid and thus increases gastric retention time (CRT) in a patient.
- API active pharmaceutical ingredient
- Another object of the invention is to provide a method for manufacturing a delayed- release pharmaceutical composition, comprising; preparing an effervescent tablet, granule, or powder containing a first effervescing organic acid component and a first effervescing base component, and adding an effective amount of an active pharmaceutical ingredient (API) coated with a delayed-release effervescent floating delivery system which, is buoyant in gastric fluid, thus increasing gastric retention rime (GRT) in a patient, wherein said tablet granule, or powder is completely solubilized in drinking water at 25 °C within 2 minutes without stirring.
- API active pharmaceutical ingredient
- Fig, 1 is a diagram showing a preferred embodiment of the manufacturing process using a LabR AM acoustic mixer
- an acid source selected from the group consisting of citric acid, tartaric acid, malic acid, fumaric acid, adipic acid, succinic acid; an anhydride of said acids; an acid salt selected from the group consisting of sodium dihydrogen phosphate, di sodium dihydrogen pyrophosphate and sodium acid sulfite and mixtures of the acids, anhydrides and acid salts.
- s carbonate source is selected from the group consisting of: sodium bicarbonate, sodium carbonate, potassium bicarbonate, potassium carbonate, sodium sesquicarbonate, sodium glycine carbonate, and mixtures thereof.
- the delayed release pharmaceutical compositions of the invention may contain a single API (e.g., metformin HO), pharmaceutically acceptable salt, hydrate, solvate, polymorph, stereoisomer, ester, prodrug and complex ⁇ thereof; or optionally may be combined with another API (e.g., metformin hydrochloride mixed with a compound selected from the group consisting of GLIPIZIDE, BLYBURIDE, PIOGLITAZONE HYDROCHLORIDE, REPAGLINIDE, ROSIGLITAZONE MALEATE, SAXAGLIPTIN and SITAGLIPTIN PHOSPHATE),
- the delayed- release effervescent floating delivery system pharmaceutical compositions ) of the invention contains the API, 2 - 10 % by weight, of a second effervescing base component (e.g., sodium bicarbonate, sodium carbonate, potassium bicarbonate, potassium carbonate, sodium sesquicarbonate. sodium glycine carbonate, and nurtures thereof), and one or more coatings such as film coating,
- coatings can be functional or non-functional.
- a functional coating helps slow the release of the active ingredient at the required site of action, in one example, the coating prevents the API from contacting the mouth or esophagus thereby masking its taste. In another example, the coating remains intact until teaching the small intestine (e.g., an enteric coating). Dissolution of a pharmaceutical composition in the mouth can be prevented with a layer or coating of hydrophilic polymers such as cellulose or gelatin. Eudragit® of various grades or other suitable polymers may be incorporated in coating compositions io release the API in the colon.
- Coating agents include, but are not limited to, polysaccharides such as maltodextrin, alkyl celluloses such as methyl or ethyl cellulose, hyclroxyalkylcelluloses (e.g. hydroxypropylcellulose or hydroxypropylniethylcelluloses); polyvinylpyrrolidone, acacia, com, sucrose, gelatin, shellac, cellulose acetate pthalate, lipids, synthetic resins, acrylic polymers, polyvinyl alcohol (PVA), copolymers of vinylpyrrolidoue arid vinyl acetate (e.g. marketed under the brand name of Plasdone ® and polymers based on methacrylic acid such as those marketed under the brand name of Eudragit®,
- polysaccharides such as maltodextrin, alkyl celluloses such as methyl or ethyl cellulose, hyclroxyalkylcelluloses (e.
- Excipients can be included along with the film formers to obtain satisfactory coatings.
- These excipients can include plasticizets such as dibutyl phthalate, methyl citrate, dibutyl sibacate, triacetine, polyethylene glycol (PEG) and the like, antitacking agents such as talc, stearic acid, magnesium steanrie and colloidal .silicon dioxide and the like, surfactants such as polysorbates and sodium lauryl sulphate, fillers such as talc, precipitated calcium carbonate, polishing agents such as beeswax, carnauba wax : synthetic chlorinated wax and opacifying agents such as titanium dioxide and the like. All these excipients can be used at levels well known to the persons skilled in the art.
- Non-permeabte coatings of insoluble polymers e.g., cellulose acetate,, ethylcellusose
- enteric coatings for delayed/modified release by .inclusion of soluble pore formers in the coating, e.g., PEG, PVA, sugars, salts, detergents, triethyl citrate, triacetin, etc.
- the coatins is a sustained release coating.
- the beads are retained in the stomach bv floating them, which also controls the drug release rate.
- Ad added agent such as alginate or polyacrylate maybe used to from a floating raft, which will trap the beads.
- Coatings of polymers that are susceptible to enzymatic cleavage by colonic bacteria are a means of ensuring release to distal ileum and ascending colon.
- Materials such as calcium pectinate can be applied as coatings to composition and multiparticulates thai disintegrate in the lower gastrointestinal tract, due to bacterial action.
- Calcium pectinate capsules for encapsulation of hioadhesive multiparticulates are also available.
- Preferred -sustained release materials are eeilulosie arid polyacrylic acid polymers (e.g.
- poltycarbophils or Eudragits These components control diffusion of water during the time it takes for the patient to swallow the efferevecent beverage.
- the acid in gastric juice will react with the second effervescent base, e.g., bicarbonate.
- the bicarbonate reacts, gas bubbles form.
- the coating ideally "gels" and traps the bicarbonate inside, making the little beads float.
- the slow release pharmaceutical compositions of the in vention can be coated by a wide variety of methods. Suitable methods include compression coating, coating in a fluidized bed or a pan and hot melt (extrusion) coating. Such methods are well known, to those skilled in the art.
- the preferred controlled-re lease coatings are applied to the API using non-aqueous systems to protect the second effervescing base component from water.
- the API core particles are mixed, with 2 to 10 wt.% of an effervescing base component, such as a bicarbonate salt (e.g., sodium bicarbonate), nanosilica (optionally), an inert media such as sucrose or glass beads, and water insoluble polymer particles, to produce coated API core particles.
- the coated API core particles are then subjected to mechanical stress, elevated temperature or a combination thereof in order to deform the coating into a continuous film.
- the coating sticks to the core API particle when it is "'pressed in place" by a hard, inert .media panicle such as sucrose. After coating the sucrose is then removed.
- the coating Includes a combination of water soluble or sweilabie coating material particles so that the water soluble or sweilabie particles are imbedded within a water insoluble, deforrnahfc continuous polymer layer.
- the API in the coated API core particles does not release immediately in the raoatn and thus the particles can be taste masked in this manner, yet the API is released in a relatively short time from the coated pharmaceutical formulation once reaching the stomach.
- the second effervescing base component can react with acid in the gastric juice to generate carbon, dioxide, causing the API particle to float on the gastric fluid and thus delay release of the API.
- Dry coating may be accomplished by any suitable device known to a skilled person. Suitable devices include, but not limited to Comil (U3 Quadro Comil of Quadro Pennsylvania, U.S.) . , LabRAM (Resodyne Minnesota, U.S.), Magnetically Assisted Impact Coater (MAIC, Aveka Minnesota, U.S.) and Fluid Energy Mill (FEM, Qualification Micronizer of Sturtevant
- the FEM is able to simultaneously mill and dry coat the particles to achieve particle sizes that are equal to or less than 50% of the initial particle size if smaller particles are desired. Dry coating of the particles cars be accomplished in a relatively short time using such equipment, for example, 100 grams of coated API core particles may he dry coated in 5 to 10 minutes using a LabRAM.
- Advantages of the present invention include reproducibility of both the high rate of solubilization of the effervescent tablet itself and the slow rate of API release.
- the present system offers flexibility in terms of release profile, compatibility of the essential components, and high uniformity of coating.
- the present method of dry particle coating is simple to implement for a wide range of API's. Coating weight is relatively low while the rate of production output per time are high.
- the invention uses biearbouat.es and acceptable salts as an essential coating material. From a temperature standpoint it is a cold coating process, which helps with excipients (no melting) and no calcination reaction in situ. Refrigeration is possible.
- the process is compatible with FR V100 componen ts, and it can be used as part of related processes, e.g., one can combine granulation with fluid bed coating plus labRAM, depending on needs and circumstances.
- the water-insoluble polymer is in particle form, with a median particle size in a range of from I ⁇ m to 20 ⁇ m, from 5 ⁇ m to 12 ⁇ m or from 5-6 ⁇ m.
- the water insoluble polymer is deformable under mechanical stress, elevated temperature or a combination thereof and thus is selected to have a Young's modulus of not greater than 420 MPa, or not greater than 200 MPa, or not greater than 100 MPa, as measured at 20 °C.
- the deformability should be equivalent to a Young's modulus of not greater than 420 MPa or not greater than 200 MPa, or not greater than 100 MPa, as measured at 20 °C when measured at elevated or reduced temperatures actually used for processing.
- elevated processing temperatures could he employed to soften the water insoluble polymer for deformation or that a combination of softening at elevated temperature and mechanical stress can be employed.
- the water insoluble polymer may be selected from easily deformatble micronized polymers.
- the water insoluble polymer may be selected from the group consisting of polyethylene,
- polypropylene polytetrafluoroethylene, carnauba wax, castor wax, polyamide wax, arsd combinations thereof.
- the water insoluble layer should allow a difYusrvity of the API in the range of 0-20
- the coatings result in a significant delay or reduction in API release for the first two to four minutes of release in a dissolution test indicative of taste-release in the mouth, while permitting complete dissolution of the effervescent tablet.
- the water soluble or swellable material is in particle form, with a median particle size in a range of from 0,5 ⁇ m to 20 ⁇ m, or in a range of from 1 ⁇ m to 10 ⁇ m.
- the water swellable material swells upon absorption of water and may be selected from typical disintegrams used m the pharmaceutical industry as additives for blends made for tableting.
- Exemplary water swellable materials include crospovidone, croscarmellose and sodium starch glycolate. Such materials, if not soluble in water, must swell upon absorption: of water such that their diameter can increase to 120-600% of their original diameter prior to water exposure, more preferably, 200-600%,
- the water soluble material has a solubility of at least 50 mg/ml in water at neutral
- the water soluble material should be readily soluble in water and have an intrinsic dissolution rate of 3-60 ⁇ g/m 2 s. Water soluble materials having higher intrinsic dissolution rates of 60-300 ⁇ g/m 2 s may also be used but should first be coated with a
- hydrophobic silica layer in an amount of 100-300% surface coverage.
- water soluble materials include micromzable materials such as sugars such as sucrose, polyols such as mannitol and sorbitol, polyvinylpyrrolidone, ethylcellulose, faydroxypropylmethylcellulose (HPMC), hydroxypropylcellulose (HPC), lactose, and poly-Cethylene oxide) (FBO),
- HydrophUic polymers are a particularly useful class of materials that may be used.
- the amount of water soluble or water swellable material employed in the mixing step is in a range of from 0.1 wt, % to 25 wt, %, or from 0.5 wt. % to 13 wt % of the total weight of the API core particles and coating materials.
- Particles coated with the water soluble or water swellable material may be optionally dry coated with hydrophobic silica to a SAC from 100%to 400% to slow the dissolution rate of the APL This option is especially beneficiall tor coming materials that dissolve and/or swell too quickly to mask the API's taste. Dry coating with hydrophobic silica may produce a poorly wetting but still soluble particle.
- the silica particles used for dry coating include hydrophobic silica or hydrophobicaily treated silica.
- Examples include Aerosil R972 silica (Degussa), CAB-O-SIL EH-5 silica (Cabot), OX-50 silica (Degassa).
- COSM055 Catalyst & Chemical md. Co. Ltd (Japan)
- P-500 hydrophilic si!ic:a Catalyst & Chemical Ind. Co, Ltd (Japan)
- TS5 silica Cabot
- more than one type of silica may be used in combination.
- POT example, TS5 and Aerosil R972 may be used together to coat the API core particles.
- the cG in also permit: at least $ ⁇ of the release of the nnc ated API core particles at 30 minutes or 60 minutes, as desired, in a standard USP dissolution test indicative of dissolutio in the Gl tract. Specifically, in the first two minutes, the release from the test sample consisting of coated particles is nearly anrestod by the coating, with less than 0.1 % of drug dissolvin in a dissolution test indicative of taste-release in the mouth, more preferably, ess than 0.01 % of drug dissolving in a dissolution test indicative of taste-release in die mouth. Also, in some
- less than about 1 % of drag dissolves in a dissolution test indicative of taste-release in the mouth at four minutes, more preferably less than 0.5 %, as compared with die release from a test sample of uucoated drug particles of comparable size.
- the polyethylene wax has a Young's Modulus o 200 MPa.
- the mixture contains 20 wt.5 sucrose media, 10 wt.% nanosilica, 5 wt.% sodium bicarbonate, and 10 wt. % metformin HO.
- the powder blend is processed using an acoustic mixer as shown in Figure 1,
- a delegable polymer, polyethylene 0»E wax having apartieJeto of 5.5 ⁇ » is used to eoat
- the mixture contains 20 wt.% sucrose med ⁇ , 10 ⁇ vt.3 ⁇ 4 aanosiiea, 5 M «od3 ⁇ 4 bic3 ⁇ 4rk>nate, and 10 t. % metformin HCI,
- the powder blend is processed vising an acoustic mixer as shown in Figure I.
- Metformin HCI particles (10 wt.%) with a volume
- PE wax medium particle size 5.5 urn
- Aerosii 972 dry coated with Aerosii 972, and lactose (18 ⁇ ) dry coated with Aerosil R972.
- the mixture contains 25 wt.% sucrose media, 1 wt.% sodium bicarbonate, The
- metformin is sometimes dosed once, and more often twice (and sometimes even three times) per day, some of these drugs used m combination (like Januvia, the DPP4 inhibitor sitagliptan, or like the SGLT2 inhibitor canigloflozin), are taken once per day.
- a cumulative daily dosing approach may be preferred.
- the desired dose were 500 .mg of metformin twice per day and 100 mg canigloflozin once per day, one could provide a dose of 500 mg metfornm plus 50 mg eanaghflozin twice per day, which keeps the drug product and dosing regimen simple.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
Abstract
A delayed-release pharmaceutical composition, comprising; an effervescent tablet, granule, or powder containing a first effervescing organic acid component and a first effervescing base component, wherein said tablet granule, or powder is completely solubilized in drinking water at 25 °C within 2 minutes without stirring; and an effective amount of active pharmaceutical ingredient (API) coated with a delayed- release effervescent floating delivery system containing a second effervescing base component, which system is buoyant, in gastric fluid and thus increases gastric retention time (GRT) in a patient
Description
Title
Effervescent Formulations That Deliver Particles Which Float in the Stomach
Field of the Invention
Effervescent delayed release formulations.
Back ground o f the Invention
Sustained- or delayed-release pharmaceutical compositions are well known and generally employ specialized coatings based on pH or water solubility effects, placed on the active phannaeeutieal ingredient (API), ft is also known that drug release rates can be delayed or controlled by delivering an API to the stomach m a floating drug delivery system having a bulk density less than gastric fluid, which system remains buoyant in the stomach for an extended period of time and increases the gastric retention time (GRT). Typically as such a system is floating on the gastric fluid the API is released slowly at the desired rate, and, after release of the drug, the residual system is emptied from the stomach resulting in better control of the fluctuations in plasma drug concentration. Floating drug delivery systems include gas-generating and non-effervescent systems. Delayed-release coatings that depend on pH or water solubility effects are sometimes combined with floating systems.
Non-effervescent floating systems typically contain cellulose derivatives like starch and a higher fatty alcohol or fatly acid glyeerkle, bilayer compressed capsules, multilayered flexible sheet-like medicament devices, hollow microspheres of acrylic resins, polystyrene floatable shells, single and multiple unit devices with floatation chambers and microporous compartments and buoyant controlled release powder formulations, or hydrogels that expand to hundreds of times their dehydrated form when immersed in water. Oral drug delivery formulations made from these gels swell rapidly in the stomach, causing medications to move more slowly from the stomach to the intestines and be absorbed more efficiently by the body.
Gas-generating systems' typically use effervescent components such as sodium bicarbonate, citric acid and tartaric acid. The stoichiometric ratio of citric acid and sodium bicarbonate optimal for gas generation is 0,76:1. The common approach for preparing these systems involves resin beads loaded with bicarbonate and coated with ethyl cellulose. The insoluble coating allows
permeation of water causing carbon dioxide to release arid the beads to float in the stomach Other appfoacb.es include the use of highly swellable hydrocolloids arid light mineral oils,- a mixture of sodium alginate and sodium bicarbonate, multiple unit floating pills that generate carbon dioxide when ingested, floating minicapsules with a core of sodium bicarbonate, lacotes and polyvinyl pytrolodone coats with hydroxypropyl methykeliulose, and floating systems based on ion exchange resin technology- Prior to the present invention, one would not expect to combine an effervescent floating system with a conventional effervescent tablet formulation for dissolving in water before ingestion by the patient. That is because commercial effervescent tablets and grannies contain relatively large amounts of the acid/base couple to -promote rapid, disintegration, so the large amount of acid would react to some extent with the effervescent compounds within the floating system before it reached the stomach.
Summary of the Invention
An object of the present invention is to provide a delayed-release pharmaceutical composition, comprising: an effervescent tablet, granule, or powder containing a first effervescing organic acid component and a first effervescing base component, wherein said tablet, granule, or powder is completely solubilized. in drinking water at 25 °C within 2 minutes without stirring; and an effective amount of active pharmaceutical ingredient (API) coated with a delayed- release effervescent floating delivery system containing a second, effervescing base component, which system is buoyant in gastric fluid and thus increases gastric retention time (CRT) in a patient.
Another object of the invention is to provide a method for manufacturing a delayed- release pharmaceutical composition, comprising; preparing an effervescent tablet, granule, or powder containing a first effervescing organic acid component and a first effervescing base component, and
adding an effective amount of an active pharmaceutical ingredient (API) coated with a delayed-release effervescent floating delivery system which, is buoyant in gastric fluid, thus increasing gastric retention rime (GRT) in a patient, wherein said tablet granule, or powder is completely solubilized in drinking water at 25 °C within 2 minutes without stirring.
Brief Description of the Figures
Fig, 1 is a diagram showing a preferred embodiment of the manufacturing process using a LabR AM acoustic mixer;
Detailed Description of the Invention
As part of the first or main effervescent systena, an acid source selected from the group consisting of citric acid, tartaric acid, malic acid, fumaric acid, adipic acid, succinic acid; an anhydride of said acids; an acid salt selected from the group consisting of sodium dihydrogen phosphate, di sodium dihydrogen pyrophosphate and sodium acid sulfite and mixtures of the acids, anhydrides and acid salts.
As part of the first or main effervescent system, s carbonate source is selected from the group consisting of: sodium bicarbonate, sodium carbonate, potassium bicarbonate, potassium carbonate, sodium sesquicarbonate, sodium glycine carbonate, and mixtures thereof.
The delayed release pharmaceutical compositions of the invention may contain a single API (e.g., metformin HO), pharmaceutically acceptable salt, hydrate, solvate, polymorph, stereoisomer, ester, prodrug and complex© thereof; or optionally may be combined with another API (e.g., metformin hydrochloride mixed with a compound selected from the group consisting of GLIPIZIDE, BLYBURIDE, PIOGLITAZONE HYDROCHLORIDE, REPAGLINIDE, ROSIGLITAZONE MALEATE, SAXAGLIPTIN and SITAGLIPTIN PHOSPHATE),
The delayed- release effervescent floating delivery system pharmaceutical compositions ) of the invention contains the API, 2 - 10 % by weight, of a second effervescing base component (e.g., sodium bicarbonate, sodium carbonate, potassium bicarbonate, potassium carbonate, sodium sesquicarbonate. sodium glycine carbonate, and nurtures thereof), and one or more coatings such as film coating, enteric coating, bioadhesrve coating, diffusion coating, and other non-water- permeable coatings known in the art.
These coatings can be functional or non-functional. A functional coating helps slow the release of the active ingredient at the required site of action, in one example, the coating prevents the API from contacting the mouth or esophagus thereby masking its taste. In another example, the coating remains intact until teaching the small intestine (e.g., an enteric coating). Dissolution of a pharmaceutical composition in the mouth can be prevented with a layer or coating of hydrophilic polymers such as cellulose or gelatin. Eudragit® of various grades or other suitable polymers may be incorporated in coating compositions io release the API in the colon.
Coating agents include, but are not limited to, polysaccharides such as maltodextrin, alkyl celluloses such as methyl or ethyl cellulose, hyclroxyalkylcelluloses (e.g. hydroxypropylcellulose or hydroxypropylniethylcelluloses); polyvinylpyrrolidone, acacia, com, sucrose, gelatin, shellac, cellulose acetate pthalate, lipids, synthetic resins, acrylic polymers, polyvinyl alcohol (PVA), copolymers of vinylpyrrolidoue arid vinyl acetate (e.g. marketed under the brand name of Plasdone ® and polymers based on methacrylic acid such as those marketed under the brand name of Eudragit®,
Excipients can be included along with the film formers to obtain satisfactory coatings. These excipients can include plasticizets such as dibutyl phthalate, methyl citrate, dibutyl sibacate, triacetine, polyethylene glycol (PEG) and the like, antitacking agents such as talc, stearic acid, magnesium steanrie and colloidal .silicon dioxide and the like, surfactants such as polysorbates and sodium lauryl sulphate, fillers such as talc, precipitated calcium carbonate, polishing agents such as beeswax, carnauba wax: synthetic chlorinated wax and opacifying agents such as titanium dioxide and the like. All these excipients can be used at levels well known to the persons skilled in the art.
4
Non-permeabte coatings of insoluble polymers, e.g., cellulose acetate,, ethylcellusose, can be used as enteric coatings for delayed/modified release by .inclusion of soluble pore formers in the coating, e.g., PEG, PVA, sugars, salts, detergents, triethyl citrate, triacetin, etc.
The coatins is a sustained release coating. The beads are retained in the stomach bv floating them, which also controls the drug release rate. Ad added agent such as alginate or polyacrylate maybe used to from a floating raft, which will trap the beads.
Coatings of polymers that are susceptible to enzymatic cleavage by colonic bacteria are a means of ensuring release to distal ileum and ascending colon. Materials such as calcium pectinate can be applied as coatings to composition and multiparticulates thai disintegrate in the lower gastrointestinal tract, due to bacterial action. Calcium pectinate capsules for encapsulation of hioadhesive multiparticulates are also available.
Preferred -sustained release materials are eeilulosie arid polyacrylic acid polymers (e.g.
poltycarbophils or Eudragits). These components control diffusion of water during the time it takes for the patient to swallow the efferevecent beverage. Once in the stomach, the acid in gastric juice will react with the second effervescent base, e.g., bicarbonate.. When the bicarbonate reacts, gas bubbles form. The coating ideally "gels" and traps the bicarbonate inside, making the little beads float.
The slow release pharmaceutical compositions of the in vention can be coated by a wide variety of methods. Suitable methods include compression coating, coating in a fluidized bed or a pan and hot melt (extrusion) coating. Such methods are well known, to those skilled in the art.
The preferred controlled-re lease coatings are applied to the API using non-aqueous systems to protect the second effervescing base component from water. in a preferred coating method, the API core particles are mixed, with 2 to 10 wt.% of an effervescing base component, such as a bicarbonate salt (e.g., sodium bicarbonate), nanosilica (optionally), an inert media such as sucrose or glass beads, and water insoluble polymer particles, to produce coated API core particles. The coated API core particles are then subjected to mechanical stress, elevated temperature or a combination thereof in order to deform the
coating into a continuous film. The coating sticks to the core API particle when it is "'pressed in place" by a hard, inert .media panicle such as sucrose. After coating the sucrose is then removed.
Optionally the coating Includes a combination of water soluble or sweilabie coating material particles so that the water soluble or sweilabie particles are imbedded within a water insoluble, deforrnahfc continuous polymer layer.
The API in the coated API core particles does not release immediately in the raoatn and thus the particles can be taste masked in this manner, yet the API is released in a relatively short time from the coated pharmaceutical formulation once reaching the stomach. At that time the second effervescing base component can react with acid in the gastric juice to generate carbon, dioxide, causing the API particle to float on the gastric fluid and thus delay release of the API.
Dry coating may be accomplished by any suitable device known to a skilled person. Suitable devices include, but not limited to Comil (U3 Quadro Comil of Quadro Pennsylvania, U.S.)., LabRAM (Resodyne Minnesota, U.S.), Magnetically Assisted Impact Coater (MAIC, Aveka Minnesota, U.S.) and Fluid Energy Mill (FEM, Qualification Micronizer of Sturtevant
Massachusetts U.S.) The FEM is able to simultaneously mill and dry coat the particles to achieve particle sizes that are equal to or less than 50% of the initial particle size if smaller particles are desired. Dry coating of the particles cars be accomplished in a relatively short time using such equipment, for example, 100 grams of coated API core particles may he dry coated in 5 to 10 minutes using a LabRAM.
Advantages of the present invention include reproducibility of both the high rate of solubilization of the effervescent tablet itself and the slow rate of API release. The present system offers flexibility in terms of release profile, compatibility of the essential components, and high uniformity of coating. The present method of dry particle coating is simple to implement for a wide range of API's. Coating weight is relatively low while the rate of production output per time are high. The invention uses biearbouat.es and acceptable salts as an essential coating material. From a temperature standpoint it is a cold coating process, which helps with excipients (no melting) and no calcination reaction in situ. Refrigeration is possible. The process is compatible with FR V100 componen ts, and it can be used as part of related processes, e.g., one
can combine granulation with fluid bed coating plus labRAM, depending on needs and circumstances.
The water-insoluble polymer is in particle form, with a median particle size in a range of from I μm to 20 μm, from 5 μm to 12 μm or from 5-6 μm. The water insoluble polymer is deformable under mechanical stress, elevated temperature or a combination thereof and thus is selected to have a Young's modulus of not greater than 420 MPa, or not greater than 200 MPa, or not greater than 100 MPa, as measured at 20 °C. Alternatively, the deformability should be equivalent to a Young's modulus of not greater than 420 MPa or not greater than 200 MPa, or not greater than 100 MPa, as measured at 20 °C when measured at elevated or reduced temperatures actually used for processing. Thus, it is contemplated, for example, that elevated processing temperatures could he employed to soften the water insoluble polymer for deformation or that a combination of softening at elevated temperature and mechanical stress can be employed.
The water insoluble polymer may be selected from easily deformatble micronized polymers. The water insoluble polymer may be selected from the group consisting of polyethylene,
polypropylene, polytetrafluoroethylene, carnauba wax, castor wax, polyamide wax, arsd combinations thereof.
The water insoluble layer should allow a difYusrvity of the API in the range of 0-20
x 10-12 m2/s or more preferable 5-15 x 10-12 m2/s. The coatings result in a significant delay or reduction in API release for the first two to four minutes of release in a dissolution test indicative of taste-release in the mouth, while permitting complete dissolution of the effervescent tablet.
The water soluble or swellable material is in particle form, with a median particle size in a range of from 0,5 μm to 20 μm, or in a range of from 1 μm to 10 μm. The water swellable material swells upon absorption of water and may be selected from typical disintegrams used m the pharmaceutical industry as additives for blends made for tableting. Exemplary water swellable materials include crospovidone, croscarmellose and sodium starch glycolate. Such materials, if
not soluble in water, must swell upon absorption: of water such that their diameter can increase to 120-600% of their original diameter prior to water exposure, more preferably, 200-600%,
The water soluble material has a solubility of at least 50 mg/ml in water at neutral
pH and 20 X. The water soluble material should be readily soluble in water and have an intrinsic dissolution rate of 3-60 μg/m2s. Water soluble materials having higher intrinsic dissolution rates of 60-300 μg/m2s may also be used but should first be coated with a
hydrophobic silica layer in an amount of 100-300% surface coverage. Examples of water soluble materials include micromzable materials such as sugars such as sucrose, polyols such as mannitol and sorbitol, polyvinylpyrrolidone, ethylcellulose, faydroxypropylmethylcellulose (HPMC), hydroxypropylcellulose (HPC), lactose, and poly-Cethylene oxide) (FBO),
polymethacrylates (Eudragit brand polymers), and combinations thereof HydrophUic polymers are a particularly useful class of materials that may be used.
The amount of water soluble or water swellable material employed in the mixing step is in a range of from 0.1 wt, % to 25 wt, %, or from 0.5 wt. % to 13 wt % of the total weight of the API core particles and coating materials.
Particles coated with the water soluble or water swellable material may be optionally dry coated with hydrophobic silica to a SAC from 100%to 400% to slow the dissolution rate of the APL This option is especially beneficiall tor coming materials that dissolve and/or swell too quickly to mask the API's taste. Dry coating with hydrophobic silica may produce a poorly wetting but still soluble particle.
The silica particles used for dry coating include hydrophobic silica or hydrophobicaily treated silica. Examples include Aerosil R972 silica (Degussa), CAB-O-SIL EH-5 silica (Cabot), OX-50 silica (Degassa). COSM055 (Catalyst & Chemical md. Co. Ltd (Japan)), P-500 hydrophilic si!ic:a (Catalyst & Chemical Ind. Co, Ltd (Japan)) and TS5 silica (Cabot). In some embodiments, more than one type of silica may be used in combination. POT example, TS5 and Aerosil R972 may be used together to coat the API core particles.
8
The cG in also permit: at least $© of the release of the nnc ated API core particles at 30 minutes or 60 minutes, as desired, in a standard USP dissolution test indicative of dissolutio in the Gl tract. Specifically, in the first two minutes, the release from the test sample consisting of coated particles is nearly anrestod by the coating, with less than 0.1 % of drug dissolvin in a dissolution test indicative of taste-release in the mouth, more preferably, ess than 0.01 % of drug dissolving in a dissolution test indicative of taste-release in die mouth. Also, in some
embodiments less than about 1 % of drag dissolves in a dissolution test indicative of taste-release in the mouth at four minutes, more preferably less than 0.5 %, as compared with die release from a test sample of uucoated drug particles of comparable size.
Example 1
A detoabie polymer, polye&yi ie (PI) wax. ing a parucie size of S.S μηι is used to coat metformin hydrochloride. The polyethylene wax has a Young's Modulus o 200 MPa. The mixture contains 20 wt.5 sucrose media, 10 wt.% nanosilica, 5 wt.% sodium bicarbonate, and 10 wt. % metformin HO. The powder blend is processed using an acoustic mixer as shown in Figure 1,
A delegable polymer, polyethylene 0»E wax having apartieJeto of 5.5 η» is used to eoat
! w x aas a Erag*s Modulus of 200 MPs. The mixture contains 20 wt.% sucrose med^ , 10 \vt.¾ aanosiiea, 5 M «od¾ bic¾rk>nate, and 10 t. % metformin HCI, The powder blend is processed vising an acoustic mixer as shown in Figure I.
Example 2
Metformin HCI particles (10 wt.%) with a volume
coated with PE wax (median particle size 5.5 urn)
as the h drophilic polymer at a
μιη) dry coated with Aerosii 972, and lactose (18 μηι) dry coated with Aerosil R972. The mixture contains 25 wt.% sucrose media, 1 wt.% sodium bicarbonate, The
9
coating formulatins with different hydrophilic polymers are all capable o f taste masking the metformin while still achieving controlled release.
For fixed dose combinations, although metformin, is sometimes dosed once, and more often twice (and sometimes even three times) per day, some of these drugs used m combination (like Januvia, the DPP4 inhibitor sitagliptan, or like the SGLT2 inhibitor canigloflozin), are taken once per day. In such instances a cumulative daily dosing approach may is preferred. For example, if the desired dose were 500 .mg of metformin twice per day and 100 mg canigloflozin once per day, one could provide a dose of 500 mg metfornm plus 50 mg eanaghflozin twice per day, which keeps the drug product and dosing regimen simple.
The foregoing examples have been presented for the purpose of illustration and description only. The scope of the .invention is to be determined from the claims appended hereto.
Claims
1. A delayed-release phannaceutica! composition, comprising: an effervescent tablet, granule, or powder containing a .first effervescing organic acid component and a first effervescing base component, wherein said tablet granule, or powder is completely solubilized in drinking water at 25 °C within 2 minutes without stirring; and. an effective amount of active pharmaceutical ingredient (API) coated with a delayed- release effervescent floating delivery system containing a second effervescing base component, which system is buoyant in gastric fluid and thus increases gastric retention time (GRT) in a patient.
2. The composition of claim 1 , wherein, the API is coated with polyethylene.
3, The composition of claim 1, wherein the API is metformin HCl.
4, The composition of claim 1 , wherein the API is a combination of Caniglaflozi« and
Metformin
5. The composition, of claim. I, wherein, the API is a. combination of Glipizide and Metformin,
6, A method for manufacturing a delayed-release pharmaceutical composition, comprising: preparing an effervescent tablet, granule, or -powder containing a .first effervescing organic acid component and a first effervescing base component, and adding an. effective amount of an active phannaceutical ingredient (API) coated with a delayed~relealse effervescent floating delivery system which, is buoyant in gastric .fluid, thus increasing gastric retention time (GRIP) in a patient, wherein said tablet, granule, or powder is completely solubilized in drinking water at 23 °C within 2 minutes wiihoui stirring.
7. The method of claim 6, wherein the API is coated with, polyethylene,
S, The method of claim 6, wherein the API is metformin HCl
9. The composition of claim 6, wherein the API is a combination of Caniglaflozin and Metformin..
10. The composition of claim 6, wherein the API is a combination of Glipizide and Metformin.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361818895P | 2013-05-02 | 2013-05-02 | |
US61/818,895 | 2013-05-02 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2014191806A2 true WO2014191806A2 (en) | 2014-12-04 |
WO2014191806A3 WO2014191806A3 (en) | 2015-02-05 |
Family
ID=51022354
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2014/000825 WO2014191806A2 (en) | 2013-05-02 | 2014-03-01 | Effervescent formulations that deliver particles which float in the stomach |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2014191806A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20200215061A1 (en) * | 2019-01-09 | 2020-07-09 | Celgene Corporation | Pharmaceutical compositions comprising (s)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile and methods of using the same |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUP0000116A3 (en) * | 1996-10-01 | 2000-08-28 | Stanford Res Inst Int | Taste-masked microcapsule compositions and methods of manufacture |
SE9702533D0 (en) * | 1997-07-01 | 1997-07-01 | Astra Ab | New oral formulation |
-
2014
- 2014-03-01 WO PCT/IB2014/000825 patent/WO2014191806A2/en active Application Filing
Non-Patent Citations (1)
Title |
---|
None |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20200215061A1 (en) * | 2019-01-09 | 2020-07-09 | Celgene Corporation | Pharmaceutical compositions comprising (s)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile and methods of using the same |
JP2022516989A (en) * | 2019-01-09 | 2022-03-03 | セルジーン コーポレイション | (S) -4- (4-((((2- (2,6-dioxopiperidine-3-yl) -1-oxoisoindoline-4-yl) oxy) methyl) benzyl) piperazine-1 -Il) -3-Fluorobenzonitrile-containing pharmaceutical composition and its usage |
US11779580B2 (en) * | 2019-01-09 | 2023-10-10 | Celgene Corporation | Pharmaceutical compositions comprising (s)-4-(4-(4- (((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrtle and methods of using the |
JP7489989B2 (en) | 2019-01-09 | 2024-05-24 | セルジーン コーポレイション | Pharmaceutical compositions comprising (S)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile and methods of use thereof |
Also Published As
Publication number | Publication date |
---|---|
WO2014191806A3 (en) | 2015-02-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6068142B2 (en) | Suspended fine granules | |
KR101489401B1 (en) | Drug delivery systems comprising weakly basic drugs and organic acids | |
KR101413613B1 (en) | Drug delivery systems comprising weakly basic selective serotonin 5-HT3 blocking agent and organic acids | |
JP5680627B2 (en) | Suspended controlled release pharmaceutical composition | |
ES2389358T3 (en) | Pharmaceutical compositions of rifaximin | |
JP2016034947A (en) | Controlled oral dosage formulations containing jak3 inhibitor | |
CA2879282C (en) | Gastro-retentive drug delivery system | |
TW200803871A (en) | New combination dosage form | |
KR20060126611A (en) | Gastric retention system | |
JP2012518655A5 (en) | ||
JP2008285500A (en) | Oral pharmacological preparation containing ibandronate | |
MX2013004468A (en) | Process for making multiparticulate gastroretentive dosage forms. | |
MXPA01012636A (en) | New formulation. | |
RU2372893C2 (en) | Coated compound containing pharmaceutical agent | |
JP2007522258A (en) | Composition for oral administration of tamsulosin hydrochloride and sustained release granule preparation thereof | |
KR20190049543A (en) | Solid formulation composition for oral administration with enhanced disintegration property and method for preparation thereof | |
CA2640472A1 (en) | Dipyridamole extended-release formulations and process for preparing same | |
EP2515863A2 (en) | Slow release pharmaceutical compositions of iloperidone | |
EP2994108A1 (en) | Oral pharmaceutical formulation | |
Goud et al. | Gastroretentive drug delivery system | |
US9119793B1 (en) | Gastroretentive dosage forms for doxycycline | |
WO2014191806A2 (en) | Effervescent formulations that deliver particles which float in the stomach | |
JP2010521437A (en) | Time-specific delay / pulse release dosage form | |
Razavi et al. | An overview on floating drug delivery systems (FDDS); conventional and new approaches for preparation and in vitro–in vivo evaluation | |
Tamizharasi et al. | Floating Drug Delivery System. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14733297 Country of ref document: EP Kind code of ref document: A2 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 14733297 Country of ref document: EP Kind code of ref document: A2 |